tiprankstipranks
Trending News
More News >
Innovent Biologics (HK:1801)
:1801
Hong Kong Market

Innovent Biologics (1801) Stock Forecast & Price Target

Compare
17 Followers
See the Price Targets and Ratings of:

1801 Analyst Ratings

Strong Buy
6Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Innovent
Biologics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1801 Stock 12 Month Forecast

Average Price Target

HK$92.24
▲(12.14%Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Innovent Biologics in the last 3 months. The average price target is HK$92.24 with a high forecast of HK$108.40 and a low forecast of HK$66.00. The average price target represents a 12.14% change from the last price of HK$82.25.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"31":"HK$31","70":"HK$70","109":"HK$109","50.5":"HK$50.5","89.5":"HK$89.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":108.40000003307826,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$108.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":92.2371633625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$92.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":66.0000000201399,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$66.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[31,50.5,70,89.5,109],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,78.4,80.7076923102368,83.01538462047358,85.32307693071037,87.63076924094716,89.93846155118395,92.24615386142074,94.55384617165753,96.86153848189431,99.1692307921311,101.47692310236789,103.78461541260468,106.09230772284147,{"y":108.40000003307826,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,78.4,79.46439718173077,80.52879436346154,81.59319154519231,82.65758872692308,83.72198590865385,84.78638309038462,85.85078027211539,86.91517745384616,87.97957463557692,89.04397181730769,90.10836899903846,91.17276618076923,{"y":92.2371633625,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,78.4,77.44615384770307,76.49230769540614,75.53846154310921,74.58461539081227,73.63076923851534,72.67692308621841,71.72307693392149,70.76923078162456,69.81538462932762,68.86153847703069,67.90769232473376,66.95384617243683,{"y":66.0000000201399,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.2,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.4,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.95,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.65,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$108.40Average Price TargetHK$92.24Lowest Price TargetHK$66.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
CLSA
HK$55.9HK$108.4
Buy
31.79%
Upside
Reiterated
07/09/25
CLSA Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
Goldman Sachs Analyst forecast on HK:1801
Ziyi ChenGoldman Sachs
Goldman Sachs
HK$74.95HK$96.22
Buy
16.98%
Upside
Reiterated
07/09/25
Goldman Sachs Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
CMB International Securities Analyst forecast on HK:1801
Jill WuCMB International Securities
CMB International Securities
HK$102.95
Buy
25.17%
Upside
Reiterated
07/07/25
Innovent Biologics: Promising Pipeline and Strategic Focus Drive Buy Rating
J.P. Morgan Analyst forecast on HK:1801
Yang HuangJ.P. Morgan
J.P. Morgan
HK$84HK$90
Buy
9.42%
Upside
Reiterated
06/30/25
J.P. Morgan Keeps Their Buy Rating on Innovent Biologics (IVBXF)
Nomura
HK$54HK$89.8
Buy
9.18%
Upside
Reiterated
06/30/25
Innovent Biologics (IVBXF) Receives a Buy from NomuraNomura/Instinet analyst Jialin Zhang raised the price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF) to HK$89.80 (from HK$54.00) while maintaining a Buy rating.
Bernstein Analyst forecast on HK:1801
Rebecca LiangBernstein
Bernstein
HK$66
Buy
-19.76%
Downside
Reiterated
06/24/25
We rate Hansoh, Innovent, and Jiangsu Hengrui Outperform; and CSPC Market-Perform.
Macquarie Analyst forecast on HK:1801
Tony RenMacquarie
Macquarie
HK$35HK$38
Sell
-53.80%
Downside
Reiterated
04/07/25
Innovent Biologics Inc. (1801:HK) (IVBXF) PT Raised to HK$38 at MacquarieMacquarie analyst Tony Ren raised the price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF) to HK$38.00 (from HK$35.00) while maintaining a Underperform rating.
Jefferies Analyst forecast on HK:1801
Cui CuiJefferies
Jefferies
HK$40
Buy
-51.37%
Downside
Reiterated
01/22/25
Innovent Biologics (IVBXF) Receives a Buy from Jefferies
Bank of America Securities Analyst forecast on HK:1801
David LiBank of America Securities
Bank of America Securities
HK$56.4HK$56.9
Buy
-30.82%
Downside
Reiterated
01/03/25
Innovent Biologics Inc. (1801:HK) (IVBXF) PT Raised to HK$56.90 at BofA SecuritiesBofA Securities analyst David Li raised the price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF) to HK$56.90 (from HK$56.40) while maintaining a Buy rating.
Morgan Stanley Analyst forecast on HK:1801
Sean Wu CFAMorgan Stanley
Morgan Stanley
HK$66.5
Buy
-19.15%
Downside
Assigned
12/23/24
Morgan Stanley Reiterates Overweight Rating on Innovent Biologics Inc. (1801:HK) (IVBXF)Morgan Stanley analyst Sean Wu reiterated an Overweight rating and HK$66.50 price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF).
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
CLSA
HK$55.9HK$108.4
Buy
31.79%
Upside
Reiterated
07/09/25
CLSA Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
Goldman Sachs Analyst forecast on HK:1801
Ziyi ChenGoldman Sachs
Goldman Sachs
HK$74.95HK$96.22
Buy
16.98%
Upside
Reiterated
07/09/25
Goldman Sachs Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
CMB International Securities Analyst forecast on HK:1801
Jill WuCMB International Securities
CMB International Securities
HK$102.95
Buy
25.17%
Upside
Reiterated
07/07/25
Innovent Biologics: Promising Pipeline and Strategic Focus Drive Buy Rating
J.P. Morgan Analyst forecast on HK:1801
Yang HuangJ.P. Morgan
J.P. Morgan
HK$84HK$90
Buy
9.42%
Upside
Reiterated
06/30/25
J.P. Morgan Keeps Their Buy Rating on Innovent Biologics (IVBXF)
Nomura
HK$54HK$89.8
Buy
9.18%
Upside
Reiterated
06/30/25
Innovent Biologics (IVBXF) Receives a Buy from NomuraNomura/Instinet analyst Jialin Zhang raised the price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF) to HK$89.80 (from HK$54.00) while maintaining a Buy rating.
Bernstein Analyst forecast on HK:1801
Rebecca LiangBernstein
Bernstein
HK$66
Buy
-19.76%
Downside
Reiterated
06/24/25
We rate Hansoh, Innovent, and Jiangsu Hengrui Outperform; and CSPC Market-Perform.
Macquarie Analyst forecast on HK:1801
Tony RenMacquarie
Macquarie
HK$35HK$38
Sell
-53.80%
Downside
Reiterated
04/07/25
Innovent Biologics Inc. (1801:HK) (IVBXF) PT Raised to HK$38 at MacquarieMacquarie analyst Tony Ren raised the price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF) to HK$38.00 (from HK$35.00) while maintaining a Underperform rating.
Jefferies Analyst forecast on HK:1801
Cui CuiJefferies
Jefferies
HK$40
Buy
-51.37%
Downside
Reiterated
01/22/25
Innovent Biologics (IVBXF) Receives a Buy from Jefferies
Bank of America Securities Analyst forecast on HK:1801
David LiBank of America Securities
Bank of America Securities
HK$56.4HK$56.9
Buy
-30.82%
Downside
Reiterated
01/03/25
Innovent Biologics Inc. (1801:HK) (IVBXF) PT Raised to HK$56.90 at BofA SecuritiesBofA Securities analyst David Li raised the price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF) to HK$56.90 (from HK$56.40) while maintaining a Buy rating.
Morgan Stanley Analyst forecast on HK:1801
Sean Wu CFAMorgan Stanley
Morgan Stanley
HK$66.5
Buy
-19.15%
Downside
Assigned
12/23/24
Morgan Stanley Reiterates Overweight Rating on Innovent Biologics Inc. (1801:HK) (IVBXF)Morgan Stanley analyst Sean Wu reiterated an Overweight rating and HK$66.50 price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Innovent Biologics

1 Month
xxx
Success Rate
6/9 ratings generated profit
67%
Average Return
+9.69%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +9.69% per trade.
3 Months
xxx
Success Rate
6/9 ratings generated profit
67%
Average Return
+11.47%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +11.47% per trade.
1 Year
Jill WuCMB International Securities
Success Rate
8/9 ratings generated profit
89%
Average Return
+60.00%
reiterated a buy rating 5 days ago
Copying Jill Wu's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +60.00% per trade.
2 Years
xxx
Success Rate
9/9 ratings generated profit
100%
Average Return
+99.82%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +99.82% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1801 Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
11
7
7
8
11
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
1
1
1
0
Strong Sell
0
0
0
0
0
total
11
8
8
9
11
In the current month, 1801 has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 1801 average Analyst price target in the past 3 months is 92.24.
Each month's total comprises the sum of three months' worth of ratings.

1801 Financial Forecast

1801 Earnings Forecast

Next quarter’s earnings estimate for 1801 is HK$0.14 with a range of HK$0.14 to HK$0.14. The previous quarter’s EPS was HK$0.20. 1801 beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.10% of the time in the same period. In the last calendar year 1801 has Outperformed its overall industry.
Next quarter’s earnings estimate for 1801 is HK$0.14 with a range of HK$0.14 to HK$0.14. The previous quarter’s EPS was HK$0.20. 1801 beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.10% of the time in the same period. In the last calendar year 1801 has Outperformed its overall industry.

1801 Sales Forecast

Next quarter’s sales forecast for 1801 is HK$6.36B with a range of HK$6.36B to HK$6.36B. The previous quarter’s sales results were HK$5.93B. 1801 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year 1801 has Outperformed its overall industry.
Next quarter’s sales forecast for 1801 is HK$6.36B with a range of HK$6.36B to HK$6.36B. The previous quarter’s sales results were HK$5.93B. 1801 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year 1801 has Outperformed its overall industry.

1801 Stock Forecast FAQ

What is HK:1801’s average 12-month price target, according to analysts?
Based on analyst ratings, Innovent Biologics’s 12-month average price target is 92.24.
    What is HK:1801’s upside potential, based on the analysts’ average price target?
    Innovent Biologics has 12.14% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Innovent Biologics a Buy, Sell or Hold?
          Innovent Biologics has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Innovent Biologics’s share price target?
            The average share price target for Innovent Biologics is 92.24. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$108.40 ,and the lowest forecast is HK$66.00. The average share price target represents 12.14% Increase from the current price of HK$82.25.
              What do analysts say about Innovent Biologics?
              Innovent Biologics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of Innovent Biologics?
                To buy shares of HK:1801, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis